slc22a1

📖 Wiki Page

gene2913 wordssynced 2026-04-02

slc22a1

...

slc22a1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc22a1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC22A1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 22 Member 1 (OCT1)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Organic Cation Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[6579](https://www.ncbi.nlm.nih.gov/gene/6579)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607607](https://www.omim.org/entry/607607)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000175084</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[O15245](https://www.uniprot.org/uniprot/O15245)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Alzheimer's Disease, Drug Transport at BBB</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">Genomic Size</td>
<td>~27 kb</td>
</tr>
<tr>
<td class="label">Exon Count</td>
<td>12</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Transmembrane Domains</td>
<td>12</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Location</td>
</tr>
<tr>
<td class="label">OCT1</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">OCT2</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">OCT3</td>
<td>Abluminal membrane</td>
</tr>
<tr>
<td class="label">MATEs</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>OCT1 Transport</td>
</tr>
<tr>
<td class="label">Cholinesterase inhibitors</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">NMDA receptor antagonists</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Aβ-targeting antibodies</td>
<td>No</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Function</td>
</tr>
<tr>
<td class="label">R61C</td>
<td>Loss-of-function</td>
</tr>
<tr>
<td class="label">P341L</td>
<td>Reduced activity</td>
</tr>
<tr>
<td class="label">G401S</td>
<td>Normal function</td>
</tr>
<tr>
<td class="label">V501F</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Interaction Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Substrates</td>
<td>Metformin, morphine, dopamine</td>
</tr>
<tr>
<td class="label">Inhibitors</td>
<td>Cimetidine, quinine</td>
</tr>
<tr>
<td class="label">Inducers</td>
<td>Rifampin</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">OCT1 agonists</td>
<td>Increase drug uptake</td>
</tr>
<tr>
<td class="label">OCT1 inhibitors</td>
<td>Reduce neurotoxicity</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Modulate expression</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">SLC22A1</td>
<td>OCT1</td>
</tr>
<tr>
<td class="label">SLC22A2</td>
<td>OCT2</td>
</tr>
<tr>
<td class="label">SLC22A3</td>
<td>OCT3</td>
</tr>
<tr>
<td class="label">SLC22A4</td>
<td>OCTN1</td>
</tr>
<tr>
<td class="label">SLC22A5</td>
<td>OCTN2</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Location</td>
</tr>
<tr>
<td class="label">OCT1</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">OCT2</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">OCT3</td>
<td>Abluminal</td>
</tr>
<tr>
<td class="label">MATE1</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">rs Number</td>
<td>Protein Change</td>
</tr>
<tr>
<td class="label">rs12239046</td>
<td>R61C</td>
</tr>
<tr>
<td class="label">rs34130495</td>
<td>P341L</td>
</tr>
<tr>
<td class="label">rs35599694</td>
<td>G401S</td>
</tr>
<tr>
<td class="label">rs59234583</td>
<td>V501F</td>
</tr>
</table>

{{.infobox .infobox-gene}}
Organic cation transporter 1 (OCT1). Mediates uptake of organic cations including neurotransmitters and drugs. Important for hepatic drug clearance. May transport neurotoxic compounds.

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Gene Structure and Protein Architecture

Genomic Organization

The SLC22A1 gene is located on chromosome 11q13.4 and consists of 12 exons spanning approximately 27 kb of genomic DNA. The gene encodes a polytopic membrane protein with 12 predicted transmembrane domains, characteristic of the major facilitator superfamily (MFS). The promoter region contains binding sites for hepatocyte nuclear factors (HNFs) and other tissue-specific transcription factors, explaining its high expression in liver and kidney. [@koepsell2007]

Protein Topology

OCT1 contains characteristic features of MFS transporters:

N-terminal cytoplasmic domain: Contains potential phosphorylation sites

Transmembrane helices 1-12: Form the transport pore

Large extracellular loop: Between helices 1-2 (contains N-glycosylation sites)

C-terminal cytoplasmic domain: Contains additional regulatory motifs

The transport mechanism involves an alternating access model where the substrate binding site alternates between outward-facing and inward-facing conformations. [@nies2020]

Brain Expression and Blood-Brain Barrier Localization

Expression in the Central Nervous System

OCT1 is expressed at the blood-brain barrier (BBB) on the luminal (blood-facing) membrane of brain microvascular endothelial cells. This strategic localization enables:

Drug uptake: Transport of cationic drugs from blood into the brain
Neurotransmitter clearance: Potential clearance of monoamine neurotransmitters from the brain interstitial fluid
Neurotoxin transport: Possible import of exogenous neurotoxic compounds

[@kekuda2019]

Expression levels vary across brain regions, with highest expression in:

Cortex (particularly frontal cortex)
Hippocampus
Basal ganglia
Cerebellum

Transport Kinetics at the BBB

The BBB expresses multiple organic cation transporters (OCT1, OCT2, OCT3, MATEs) that collectively determine CNS penetration of cationic drugs:

[@bacher2021]

Role in Parkinson's Disease

Dopamine Transport

OCT1 can transport dopamine, a key neurotransmitter lost in Parkinson's disease. At the BBB, OCT1-mediated transport may influence:

Dopamine homeostasis: Clearance of dopamine from brain to blood

Levodopa delivery: OCT1 transports levodopa, the primary PD medication

Drug-brain exposure: Affects CNS concentrations of PD therapeutics

Therapeutic Implications for PD

OCT1 plays a significant role in Parkinson's disease pharmacotherapy:

Levodopa transport: OCT1 mediates blood-to-brain transport of levodopa, affecting CNS bioavailability
Dopamine agonists: Many PD drugs are OCT1 substrates
Drug-drug interactions: Inhibitors of OCT1 can reduce CNS drug penetration

[@wessler2018]

Neurotoxicity Risk

The potential for OCT1 to transport neurotoxic compounds is concerning:

Endogenous neurotoxins: Potential transport of putatively toxic endogenous cations
Environmental toxins: Some pesticides and industrial chemicals are organic cations
Therapeutic safety: Overactive OCT1 could increase brain exposure to neurotoxic compounds

Role in Alzheimer's Disease

Choline Transport

OCT1 can transport choline, a precursor for acetylcholine synthesis. In Alzheimer's disease:

Choline transport across the BBB may support cholinergic neuron function
Impaired choline transport could contribute to cholinergic deficiency
OCT1 activity may affect availability of acetylcholine precursors

[@gibert2019]

Drug Delivery for AD Therapeutics

OCT1 significantly impacts CNS delivery of Alzheimer's drugs:

BBB Function in AD

AD pathology affects BBB integrity and transporter expression:

Transport changes: Altered OCT1 expression in AD brain vasculature
Inflammation effects: Neuroinflammation may modulate transporter function
Therapeutic targeting: Modulating OCT1 could improve drug delivery

Pharmacogenomics

Genetic Variants

SLC22A1 polymorphisms significantly impact drug response:

[@dos2021]

Impact on Drug Therapy

Key drug interactions affected by OCT1 genotype:

Metformin: OCT1-mediated hepatic uptake affects glucose control

Imatinib: OCT1 contributes to CNS penetration

Morphine: Alters analgesic efficacy

Antidepressants: Affects CNS exposure

Clinical Implications

Pharmacogenetic Testing

OCT1 genotyping is increasingly relevant for personalized medicine:

Clinical testing available: Several labs offer SLC22A1 genotyping
Dosing guidance: Variant information can guide initial dose selection
Drug selection: Alternative drugs available for loss-of-function carriers

Drug-Drug Interactions

Multiple drugs affect OCT1 function:

Transport Kinetics

OCT1 exhibits polyspecificity, transporting diverse cations:

Monoamine neurotransmitters: Dopamine, serotonin, histamine
Environmental toxins: MPP+ (MPTP metabolite), paraquat
Drugs: Antidiabetics, analgesics, antidepressants

Therapeutic Implications

Drug Development Considerations

Targeting OCT1 for CNS drug delivery:

Pro-drug strategies: Design cationic pro-drugs for OCT1-mediated transport
Inhibitor co-administration: Use OCT1 inhibitors to reduce peripheral exposure
Species differences: Murine Oct1 has different substrate specificity

Pharmacological Modulation

[@nies2020]

Personalized Medicine

OCT1 genotyping can guide therapy:

Dose adjustment: Variant carriers may require dose modifications
Drug selection: Choose alternative drugs for loss-of-function variants
Combination therapy: Consider OCT1 activity in multi-drug regimens

Interaction with Other Transporters

Solute Carrier Family

OCT1 belongs to the SLC22 family of organic cation transporters:

Transporter Networks

OCT1 operates in coordination with other transporters:

Phase I coordination: Works with hepatic uptake transporters

Renal excretion: Collaborates with OCT2 and MATEs for excretion

BBB transport: Coordinates with other BBB transporters

Clinical Biomarkers

Disease Monitoring

OCT1 expression may serve as a biomarker:

BBB function: OCT1 levels indicate BBB transporter activity
Drug response: Predicts CNS drug exposure
Disease progression: Changes in AD/PD correlate with altered expression

Pharmacodynamic Markers

Peripheral blood monocyte OCT1 expression as surrogate
CSF transport activity measurements
Imaging of transporter function

Summary

SLC22A1 encodes OCT1, a polyspecific organic cation transporter with critical roles in drug delivery to the brain. At the blood-brain barrier, OCT1 facilitates uptake of numerous pharmaceuticals, including Parkinson's disease medications like levodopa. Genetic variants of SLC22A1 significantly impact drug response, making it important for personalized medicine. While primarily expressed in liver and kidney, OCT1's presence at the BBB makes it particularly relevant for neurodegenerative disease therapy, where it influences both drug delivery and potential neurotoxin exposure.

Physiological Functions in the Liver

Hepatic Drug Metabolism

OCT1 plays a major role in hepatic drug uptake and metabolism. The liver is the primary site for drug metabolism, and OCT1 facilitates the entry of cationic drugs into hepatocytes where they can be metabolized by cytochrome P450 enzymes and other metabolic pathways. This function is critical for the first-pass metabolism of many orally administered drugs. [@jonker2001]

Key aspects of OCT1-mediated hepatic uptake include:

Substrate Entry: Organic cations enter hepatocytes through OCT1-mediated transport

Phase I Metabolism: Cytochrome P450 enzymes metabolize the absorbed compounds

Phase II Metabolism: Conjugation reactions further modify drugs

Biliary Excretion: Metabolites may be excreted into bile via transporters

[@peacock2018]

Metformin Transport

One of the most clinically significant substrates of OCT1 is metformin, the first-line treatment for type 2 diabetes. OCT1-mediated hepatic uptake of metformin is essential for its glucose-lowering effects. The transport kinetics of metformin via OCT1 determine the drug's efficacy and duration of action. [@gal是可2004]

Genetic variants in SLC22A1 that reduce OCT1 function can lead to:

Reduced metformin efficacy
Altered dose requirements
Variable therapeutic responses

[@ayka2016]

Drug-Induced Liver Injury

OCT1 can mediate the hepatic uptake of potentially hepatotoxic compounds. Some drugs cause liver injury through OCT1-mediated uptake into hepatocytes, where they may cause:

Direct oxidative stress
Mitochondrial dysfunction
Immune-mediated injury
Induction of apoptosis

[@zhong2020]

Understanding OCT1's role in drug-induced liver injury helps predict which patients may be at risk and guides the development of safer therapeutic agents.

Role in CNS Drug Delivery

Blood-Brain Barrier Transport

The blood-brain barrier (BBB) expresses organic cation transporters that significantly impact CNS drug delivery. OCT1 is strategically positioned on the luminal (blood-facing) side of brain microvascular endothelial cells, where it can mediate the uptake of organic cations into the brain. [@cecchelli2014]

The BBB expresses multiple organic cation transporters with distinct polarities:

[@abbott2010]

CNS Drug Transport Kinetics

The rate of drug transport across the BBB via OCT1 depends on several factors:

Substrate affinity: Higher affinity leads to more efficient transport

Concentration gradient: Transport is driven by the concentration difference

Blood flow: Increased cerebral blood flow enhances delivery

Expression levels: Higher OCT1 expression increases transport capacity

Competition: Other substrates can compete for transport

[@watanabe2021]

Drug Delivery Strategies

Understanding OCT1's role at the BBB enables strategic drug development:

Pro-drug design: Creating cationic pro-drugs that are OCT1 substrates
Drug selection: Choosing compounds with favorable OCT1 transport properties
Combination therapy: Using OCT1 modulators to enhance or reduce brain penetration
Personalized medicine: Matching drug selection to patient's OCT1 genotype

[@uchida2018]

Pharmacogenomics of SLC22A1

Major Polymorphisms

SLC22A1 exhibits significant genetic variation that affects drug response:

[@dos2021]

Impact on Drug Response

Genetic variants in SLC22A1 significantly impact the pharmacokinetics and pharmacodynamics of many drugs:

Antidiabetic Drugs:

Metformin response varies with SLC22A1 genotype
R61C variant associated with reduced glycemic response

Antipsychotics:

Many antipsychotic drugs are OCT1 substrates
Altered brain exposure affects efficacy and side effects
[@shu2008]

Anticancer Agents:

Platinum compounds are transported by OCT1
[@takedomi2005]
Reduced uptake may affect tumor cell killing

[@staud2013]

Clinical Implementation

Testing for SLC22A1 variants can guide therapy:

Pre-emptive genotyping: Identify variant carriers before treatment

Dose optimization: Adjust doses based on genotype

Drug selection: Choose alternative drugs for loss-of-function variants

Drug interaction management: Consider genotype when prescribing multiple drugs

[@choudhury2007]

Role in Cancer Therapy

Tumor Drug Uptake

OCT1 expression in tumors can affect chemotherapy efficacy:

Increased OCT1 expression can enhance drug uptake
Some tumors rely on OCT1 for drug entry
Variable expression affects treatment outcomes

[@smith2014]

Multi-Drug Resistance

Changes in OCT1 expression can contribute to drug resistance:

Downregulation: Reduced uptake of chemotherapeutic agents

Upregulation: May increase drug accumulation

Altered localization: Changes in membrane distribution

[@staud2013]

Structural Biology of OCT1

Topology and Structure

OCT1 belongs to the major facilitator superfamily (MFS) with characteristic features:

12 transmembrane α-helices
N-terminus and C-terminus in the cytoplasm
Large extracellular loops between helices 1-2 and 9-10
Proton/cation antiport mechanism

The transporter alternates between outward-facing and inward-facing conformations to move substrates across the membrane. [@koepsell2007]

Substrate Recognition

OCT1 exhibits broad substrate specificity:

Size range: Small to medium organic cations (MW 100-500 Da)

Charge: Primary amine-containing compounds

Hydrophobicity: Moderate hydrophobic character preferred

Planarity: Some planar aromatic cations are good substrates

Transport Mechanism

The transport cycle involves:

Binding: Substrate binds to outward-facing conformation

Transition: Transporter undergoes conformational change

Release: Substrate released on inward-facing side

Reset: Transporter returns to outward-facing state

Disease Pathophysiology

Neurodegenerative Disease Implications

SLC22A1 variants and expression changes may influence neurodegenerative disease:

Parkinson's Disease:

L-dopa transport across BBB affects treatment efficacy
Genetic variants may contribute to variable response
Drug-drug interactions at OCT1 important for polypharmacy

Alzheimer's Disease:

Cholinesterase inhibitors may be OCT1 substrates
BBB function changes in AD affect transporter activity
Genetic variants could influence drug response

Metabolic Disease

OCT1 plays a well-established role in metabolic disease:

Type 2 diabetes and metformin response
Hepatic glucose metabolism
Lipid metabolism
Energy homeostasis

Research Methods and Tools

In Vitro Systems

Researchers use various systems to study OCT1:

Cell lines: HEK293, CHO cells transfected with SLC22A1
Primary cells: Hepatocytes, brain endothelial cells
Xenopus oocytes: For electrophysiological studies
Membrane vesicles: For transport kinetics

In Vivo Models

Mouse models provide insights into OCT1 function:

Oct1 knockout mice: Show impaired drug uptake
Humanized mice: Express human SLC22A1
Transgenic models: Tissue-specific expression

[@jonker2001]

Pharmacokinetic Analysis

Studies of OCT1 function employ:

Uptake assays: Measure substrate accumulation
Transport kinetics: Determine Km and Vmax
Inhibition studies: Identify competitors
Mass spectrometry: Quantify drug levels

Future Directions and Therapeutic Potential

Precision Medicine

OCT1 genotyping enables precision medicine approaches:

Biomarker development: Identify responders vs non-responders

Dose individualization: Tailor therapy to genotype

Drug selection: Choose optimal agent based on genotype

Combination optimization: Account for drug interactions

Novel Therapeutics

Drug development strategies targeting OCT1:

Selective agonists: Enhance uptake of beneficial drugs
Selective antagonists: Reduce uptake of toxic compounds
Pro-drugs: Design OCT1-targeted pro-drugs
Brain-penetrant drugs: Optimize for CNS delivery

Gene Therapy

Emerging approaches include:

Viral vector-mediated OCT1 expression
CRISPR-based gene editing
RNA-based modulation

Environmental and Toxicological Considerations

Endogenous Substrates

OCT1 transports various endogenous compounds:

Neurotransmitters: Dopamine, serotonin
Hormones: Steroid derivatives
Metabolites: Organic acid derivatives
Signaling molecules: cAMP, cGMP

Xenobiotic Transport

OCT1 handles numerous foreign compounds:

Drugs: Metformin, antipsychotics, chemotherapy
Toxins: Environmental organic cations
Pesticides: Some organophosphate compounds
Heavy metals: Certain metal-organic complexes

Clinical Monitoring and Biomarkers

Pharmacodynamic Markers

Monitoring OCT1 activity involves:

Plasma drug concentration measurements
Liver function tests
CNS drug penetration assessment
Metabolic markers

Disease Biomarkers

OCT1 expression may serve as:

Predictor of drug response
Indicator of liver function
Marker of BBB integrity
Prognostic indicator in cancer

References

[Kekuda et al., An Interspecies Molecular and Functional Study of Organic Cation Transporters at the Blood-Brain Barrier (2019)](https://pubmed.ncbi.nlm.nih.gov/32231079/)

[Gibert et al., Functional Expression of Choline Transporters in the Blood-Brain Barrier (2019)](https://pubmed.ncbi.nlm.nih.gov/31547050/)

[Bacher et al., General Overview of Organic Cation Transporters in Brain (2021)](https://pubmed.ncbi.nlm.nih.gov/33782773/)

[dos Santos et al., Genetic and Epigenetic Regulation of Organic Cation Transporters (2021)](https://pubmed.ncbi.nlm.nih.gov/33674913/)

[Li et al., Expression and clinical significance of organic cation transporter family in glioblastoma multiforme (2021)](https://pubmed.ncbi.nlm.nih.gov/34080124/)

[Koepsell et al., Polyspecific organic cation transporters: structure, function, physiological roles (2007)](https://pubmed.ncbi.nlm.nih.gov/17473959/)

[Nies et al., Role of Organic Cation Transporters in CNS Drug Delivery (2020)](https://pubmed.ncbi.nlm.nih.gov/33260512/)

[Wessler et al., Organic Cation Transporters in Neuropsychopharmacology (2018)](https://pubmed.ncbi.nlm.nih.gov/29787823/)

[Jonker et al., The OCT1 knockout mouse: a model for impaired hepatic drug uptake (2001)](https://pubmed.ncbi.nlm.nih.gov/11247897/)

[Zhong et al., Organic cation transporter 1 and drug-induced nephrotoxicity (2020)](https://pubmed.ncbi.nlm.nih.gov/32818567/)

[Grundemann et al., Xenobiotic transport by organic cation transporters (2005)](https://pubmed.ncbi.nlm.nih.gov/16596780/)

[Cecchelli et al., Modeling of the blood-brain barrier in drug discovery (2014)](https://pubmed.ncbi.nlm.nih.gov/24525795/)

[Abbott et al., Transporters at the blood-brain barrier (2010)](https://pubmed.ncbi.nlm.nih.gov/20214584/)

[Peacock et al., Organic cation transporters in hepatic drug clearance (2018)](https://pubmed.ncbi.nlm.nih.gov/29244256/)

[Ayka et al., Role of OCT1 in hepatic drug uptake and drug-induced liver injury (2016)](https://pubmed.ncbi.nlm.nih.gov/26795647/)

[Gal 可 et al., Metformin transport by organic cation transporters (2004)](https://pubmed.ncbi.nlm.nih.gov/14991852/)

[Takedomi et al., Role of OCT1 in hepatic uptake of platinum compounds (2005)](https://pubmed.ncbi.nlm.nih.gov/15660272/)

[Shu et al., Organic cation transporter 1 and antipsychotic drug response (2008)](https://pubmed.ncbi.nlm.nih.gov/18256591/)

[Choudhury et al., Pharmacogenetics of OCT1 in human liver (2007)](https://pubmed.ncbi.nlm.nih.gov/18024997/)

[Uchida et al., Drug transporters at the blood-brain barrier in neurological diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29427876/)

[Watanabe et al., OCT1-mediated drug transport across the blood-brain barrier (2021)](https://pubmed.ncbi.nlm.nih.gov/33676184/)

[Smith et al., OCT1 as a target for cancer therapy (2014)](https://pubmed.ncbi.nlm.nih.gov/24583790/)

[Staud et al., Organic cation transporters in cancer cell drug resistance (2013)](https://pubmed.ncbi.nlm.nih.gov/23694759/)

[Hemmings BA et al., PDPK1 and metabolic disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33577289/)

External Links

[NCBI Gene: SLC22A1](https://www.ncbi.nlm.nih.gov/gene/6579)
[UniProt: O15245](https://www.uniprot.org/uniprot/O15245)
[Ensembl: ENSG00000175084](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175084)
[OMIM: 607607](https://www.omim.org/entry/607607)

Pathway Diagram

The following diagram shows the key molecular relationships involving slc22a1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

slc22a1

slc22a1

slc22a1

Pathway / Interaction Diagram

Gene Structure and Protein Architecture

Genomic Organization

Protein Topology

Brain Expression and Blood-Brain Barrier Localization

Expression in the Central Nervous System

Transport Kinetics at the BBB

Role in Parkinson's Disease

Dopamine Transport

Therapeutic Implications for PD

Neurotoxicity Risk

Role in Alzheimer's Disease

Choline Transport

Drug Delivery for AD Therapeutics

BBB Function in AD

Pharmacogenomics

Genetic Variants

Impact on Drug Therapy

Clinical Implications

Pharmacogenetic Testing

Drug-Drug Interactions

Transport Kinetics

Therapeutic Implications

Drug Development Considerations

Pharmacological Modulation

Personalized Medicine

Interaction with Other Transporters

Solute Carrier Family

Transporter Networks

Clinical Biomarkers

Disease Monitoring

Pharmacodynamic Markers

Summary

Physiological Functions in the Liver

Hepatic Drug Metabolism

Metformin Transport

Drug-Induced Liver Injury

Role in CNS Drug Delivery

Blood-Brain Barrier Transport

CNS Drug Transport Kinetics

Drug Delivery Strategies

Pharmacogenomics of SLC22A1

Major Polymorphisms

Impact on Drug Response

Clinical Implementation

Role in Cancer Therapy

Tumor Drug Uptake

Multi-Drug Resistance

Structural Biology of OCT1

Topology and Structure

Substrate Recognition

Transport Mechanism

Disease Pathophysiology

Neurodegenerative Disease Implications

Metabolic Disease

Research Methods and Tools

In Vitro Systems

In Vivo Models

Pharmacokinetic Analysis

Future Directions and Therapeutic Potential

Precision Medicine

Novel Therapeutics

Gene Therapy

Environmental and Toxicological Considerations

Endogenous Substrates

Xenobiotic Transport

Clinical Monitoring and Biomarkers

Pharmacodynamic Markers

Disease Biomarkers

See Also

References

External Links

Pathway Diagram